Scarica l'app Stockscreener
3.36
2.61%
-0.09
Pre-mercato:
3.41
0.05
+1.49%
Precedente Chiudi:
$3.45
Aprire:
$3.49
Volume 24 ore:
6.31M
Relative Volume:
1.92
Capitalizzazione di mercato:
$554.11M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-168.00
EPS:
-0.02
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
+1.82%
1M Prestazione:
+62.32%
6M Prestazione:
+579.34%
1 anno Prestazione:
+200.00%
Intervallo 1D:
$3.06
$3.49
Intervallo di 1 settimana:
$3.06
$3.49
Portata 52W:
$0.40
$3.49
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta CTMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.36 | 568.95M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
How CytomX Therapeutics Inc. stock compares to market leaders2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Key metrics from CytomX Therapeutics Inc.’s quarterly dataJuly 2025 Sentiment & Fast Gain Swing Alerts - newser.com
CytomX Therapeutics Inc. stock trend outlook and recovery path2025 Price Action Summary & High Conviction Investment Ideas - newser.com
Can CytomX Therapeutics Inc. rally from current levelsNew Guidance & AI Powered Market Trend Analysis - newser.com
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Down 7%Should You Sell? - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Developing predictive dashboards with CytomX Therapeutics Inc. dataJuly 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
CytomX Therapeutics (NASDAQ:CTMX) Raised to "Hold (C-)" at Weiss Ratings - MarketBeat
Custom watchlist performance reports with CytomX Therapeutics Inc.2025 Breakouts & Breakdowns & Real-Time Volume Triggers - newser.com
Intraday pattern recognizer results for CytomX Therapeutics Inc.Weekly Market Summary & Safe Entry Zone Identification - newser.com
Why CytomX Therapeutics Inc. (6C1) stock is a strong analyst pickJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
Exit strategy if you’re trapped in CytomX Therapeutics Inc.Entry Point & Low Risk Entry Point Tips - newser.com
CytomX: A Fresh Start With New Drugs After Total Pipeline Failure (NASDAQ:CTMX) - Seeking Alpha
Will CytomX Therapeutics Inc. stock maintain dividend yieldPortfolio Profit Report & Reliable Price Breakout Alerts - newser.com
Detecting price anomalies in CytomX Therapeutics Inc. with AIEarnings Performance Report & Risk Managed Trade Strategies - newser.com
Is CytomX Therapeutics Inc. (6C1) stock attractive for growth fundsWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Multi factor analysis applied to CytomX Therapeutics Inc.July 2025 Breakouts & Precise Trade Entry Recommendations - newser.com
Risk adjusted return profile for CytomX Therapeutics Inc. analyzedMarket Trend Report & Intraday High Probability Setup Alerts - newser.com
Using AI based signals to follow CytomX Therapeutics Inc.2025 Buyback Activity & Precise Buy Zone Tips - newser.com
Will CytomX Therapeutics Inc. (6C1) stock beat international competitionTrade Volume Report & Free Technical Confirmation Trade Alerts - newser.com
CytomX Therapeutics Hits New 52-Week High of $3.48, Up 105.52% - Markets Mojo
CytomX Therapeutics Hits New 52-Week High at $3.28 - Markets Mojo
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Down 3.8%Should You Sell? - MarketBeat
Is CytomX Therapeutics Inc. stock ready for a breakoutQuarterly Risk Review & Weekly Chart Analysis and Trade Guides - newser.com
Will CytomX Therapeutics Inc. stock continue dividend increasesBuy Signal & Risk Controlled Stock Alerts - newser.com
Is CytomX Therapeutics Inc. stock reversal real or fakeQuarterly Portfolio Report & Expert Approved Momentum Trade Ideas - newser.com
What drives CytomX Therapeutics Inc stock priceStock Price Forecasts & Free Superior Trading Gains - earlytimes.in
What earnings margins imply for CytomX Therapeutics Inc. (6C1) stockJuly 2025 PostEarnings & Community Trade Idea Sharing Platform - newser.com
What technical signals suggest for CytomX Therapeutics Inc. stock - newser.com
What analysts say about CytomX Therapeutics Inc stockMarket Timing Techniques & High Yield Trading Signals - earlytimes.in
How CytomX Therapeutics Inc. stock performs during Fed tightening cyclesTrade Volume Summary & Accurate Trade Setup Notifications - newser.com
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytomx Therapeutics Inc Azioni (CTMX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ogden Christopher | Chief Financial Officer |
Jun 16 '25 |
Sale |
2.69 |
10,614 |
28,540 |
226,271 |
| Ogden Christopher | Chief Financial Officer |
Jun 13 '25 |
Sale |
2.95 |
1,641 |
4,841 |
199,385 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 13 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
286,136 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 16 '25 |
Sale |
2.69 |
13,884 |
37,334 |
272,252 |
| McCarthy Sean A. | CEO |
Jun 13 '25 |
Option Exercise |
0.00 |
150,000 |
0 |
1,145,195 |
| McCarthy Sean A. | CEO |
Jun 16 '25 |
Sale |
2.69 |
55,511 |
149,264 |
1,089,684 |
| McCarthy Sean A. | CEO |
Mar 18 '25 |
Sale |
0.60 |
37,656 |
22,556 |
995,195 |
| Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
| Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
| ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):